Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Liraglutide & CV Events in Patients with T2D & CKD

Circulation; ePub 2018 Oct 3; Mann, et al

As an adjunct to standard of care in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), liraglutide reduced the risk for major cardiovascular (CV) events and all-cause mortality. In the LEADER trial, patients were randomized 1:1 to liraglutide or placebo, both in addition to standard of care. The primary outcome was composite of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke and the secondary outcomes included all-cause mortality and individual components of the primary composite outcome. Researchers found:

  • Overall, 2,158 and 7,182 patients had baseline eGFR <60 or ≥60 mL/min/1.73 m2, respectively.
  • In patients with eGFR <60 mL/min/1.73 m2, risk reduction for the primary composite CV outcome with liraglutide was greater (hazard ratio [HR] 0.69) vs those with eGFR ≥60 mL/min/1.73 m2 (HR 0.94).
  • There was no consistent effect modification with liraglutide across finer eGFR subgroups.

Citation:

Mann JFE, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes and chronic kidney disease: Results from the LEADER Trial. [Published online ahead of print October 3, 2018]. Circulation. doi:10.1161/CIRCULATIONAHA.118.036418.